<DOC>
	<DOCNO>NCT00006108</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining chemotherapy monoclonal antibody therapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine capecitabine , paclitaxel , trastuzumab treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Capecitabine , Paclitaxel , Trastuzumab Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose capecitabine administer combination paclitaxel trastuzumab ( Herceptin ) patient metastatic breast cancer . II . Determine response rate patient treatment regimen . III . Determine median time treatment failure patient treatment regimen . IV . Determine incidence cardiac toxicity patient treatment regimen . V. Assess quality life patient . OUTLINE : This dose escalation study capecitabine . Patients receive trastuzumab ( Herceptin ) IV 30-90 minute day 1 , 8 , 15 ; paclitaxel IV 3 hour day 2 ; oral capecitabine day 3-16 . Treatment repeat every 21 day least 3 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Once MTD determine , additional patient accrue . Quality life assess baseline 3 course treatment . PROJECTED ACCRUAL : A total 3-30 patient accrued phase I dose escalation portion study . A total 28-41 patient accrue phase II portion study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Metastatic disease HER2 overexpressing tumor ( 2+ 3+ ) Bidimensionally measurable evaluable disease Hormone receptor status : Estrogen receptor positive negative PATIENT CHARACTERISTICS : Age : 18 59 Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal Renal : Creatinine le 1.5 mg/dL Cardiovascular : Ejection fraction least 50 % MUGA No history congestive heart failure No uncontrolled cardiac arrhythmia Other : No prior malignancy except squamous cell basal cell carcinoma skin , noninvasive ductal carcinoma breast , cervical dysplasia No prior motor sensory neuropathy grade 2 high Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior trastuzumab ( Herceptin ) No concurrent hematopoietic growth factor Chemotherapy : No prior chemotherapy metastatic disease Prior adjuvant chemotherapy allow ( include regimen contain doxorubicin ) No prior paclitaxel , 24 hour infusion fluorouracil , capecitabine Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 50 % bone marrow Surgery : Not specify Other : No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>